Eloxx Pharmaceuticals, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Eloxx Pharmaceuticals, Inc. now
Current reporting with the operating signal separated from the noise.
Eloxx Pharmaceuticals, Inc. Announces Pricing of $66.0 Million Public Offering and Uplisting to Nasdaq
The story matters when it changes Eloxx Pharmaceuticals, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Eloxx Pharmaceuticals, Inc. (ELOX) CEO Greg Williams on Q4 2020 Results
The story matters when it changes Eloxx Pharmaceuticals, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Latest ELOX filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Eloxx Pharmaceuticals, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →